Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
73,771.01
(
0.02%
)
News Focus
News Focus
Post# of 20689
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123040
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biopearl post# 18311

Wednesday, 03/21/2018 11:16:34 AM

Wednesday, March 21, 2018 11:16:34 AM

Post# of 20689
The short answer: M281 and (especially) M254 appear to have more commercial potential than anyone (including MNTA) previously thought. For investors, this has offset the demise of the Copaxone program as a material profit engine and the stretched-out target date for product revenue from the FoB programs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote